A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer-Reference-Cited by-同舟云学术

A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer

Published:2009-10 Issue:1 Volume:66 Page:97-102
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Blakely L. Johnetta,Schwartzberg Lee,Keaton Mark,Schnell Fred,Henry David,Epperson Amanda,Walker Mark S.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. Cancer facts and figures;American Cancer Society,2007

2. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel;Gridelli;J Clin Oncol,2005

3. Combination therapy versus single agent chemotherapy in non-small cell lung cancer;Cheong;Expert Opin Pharmacother,2005

4. ASCO/FDA. ASCO/FDA Lung Cancer Endpoints Workshop, Final Summary; 2003.

5. Age and the treatment of lung cancer;Brown;Thorax,1996

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review);International Journal of Oncology;2015-10-29

2. A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer;Journal of Thoracic Oncology;2012-01

3. A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study);British Journal of Cancer;2011-09-20

4. Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach;Journal of Thoracic Oncology;2011-04

5. Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine;Chinese Journal of Integrative Medicine;2011-02-27